<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>OBJECTIVE: To define the prevalence of acquired red cell <z:e sem="disease" ids="C0520572" disease_type="Disease or Syndrome" abbrv="">enzymopathy</z:e> in <z:hpo ids='HP_0001909'>leukemia</z:hpo> and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> patients and explore its clinical significance </plain></SENT>
<SENT sid="1" pm="."><plain>METHODS: Red cell enzymes (G6PD, 6PGD, PK, ENOL, <z:chebi fb="36" ids="39048">ADA</z:chebi>, PNP,<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">ALD</z:e>) activities and PK,<z:chebi fb="36" ids="39048">ADA</z:chebi> isoenzymes were assayed by the methods recommended by ICSH and PAGE electrophoresis </plain></SENT>
<SENT sid="2" pm="."><plain>RESULTS: The prevalence rate of <z:e sem="disease" ids="C0017758" disease_type="Disease or Syndrome" abbrv="">G6PD deficiency</z:e> was 43.1%, and of PK deficiency was 27.8%, in <z:hpo ids='HP_0001909'>leukemia</z:hpo> and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> patients </plain></SENT>
<SENT sid="3" pm="."><plain>The prevalence rates of PK, G6PD and <z:e sem="disease" ids="C0268125" disease_type="Disease or Syndrome" abbrv="">PNP deficiency</z:e> in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> patients were 50%, 48% and 39.1%, respectively, while of <z:chebi fb="36" ids="39048">ADA</z:chebi>, ENOL and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">ALD</z:e> over production in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> patients were 69 </plain></SENT>
<SENT sid="4" pm="."><plain>6%, 40% and 30 </plain></SENT>
<SENT sid="5" pm="."><plain>4%, respectively </plain></SENT>
<SENT sid="6" pm="."><plain>PK activity was increased in <z:mp ids='MP_0005481'>CML</z:mp>, while the PK isoenzyme pattern was <z:mpath ids='MPATH_458'>normal</z:mpath> </plain></SENT>
<SENT sid="7" pm="."><plain>Administration of antitumor antibiotics to AL decreased G6PD and 6PGD activities (P &lt; 0.05) </plain></SENT>
<SENT sid="8" pm="."><plain>ADA2 was expressed in MNC of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> (M4 and M5) and in RBC of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CMML</z:e>, but not expressed in ALL (P &lt; 0.001) </plain></SENT>
<SENT sid="9" pm="."><plain>CONCLUSION: Determination of enzymes may be used as prognostic parameters in <z:mp ids='MP_0005481'>CML</z:mp>,a predictor of antitumor drug resistance in <z:hpo ids='HP_0002488'>acute leukemia</z:hpo>, and a differential parameter between <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>-RA and <z:hpo ids='HP_0001915'>aplastic anemia</z:hpo> and between <z:mp ids='MP_0005481'>CML</z:mp> and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CMML</z:e> </plain></SENT>
</text></document>